Figure 1 Simplified EULAR and GRAPPA

Slides:

Advertisements

Similar presentations

Nat. Rev. Rheumatol. doi: /nrrheum

Advertisements

Psoriatic Arthritis.

Immunohistochemical (IHC) staining for CD68/CD21 and CD3/CD20 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral.

Objective Target population: patients with psoriatic arthritis (PsA)

Summary of TB cases across indications and trial periods

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Enthesitis versus synovitis

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Induction of immune tolerance

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 3 Simplified EULAR and GRAPPA

Figure 2 Simplified EULAR and GRAPPA

Figure 3 Transcriptome studies performed in the target

Figure 2 Shared genetic loci in systemic autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.

Understanding Comparative Effectiveness Data in Psoriatic Arthritis

Biotherapeutics.

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 2 Overlap of associated loci among five rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Statistical approaches for the analysis of metabolomic data

Nat. Rev. Rheumatol. doi: /nrrheum

Immunohistochemical (IHC) staining for CD117 on synovial tissue (ST) of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis.

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 3 Multi-hit model for autoimmune diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Updated 2016 PsA Core Domain Set.

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Percentage of patients achieving EULAR response

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Reproductive health in patients with rheumatic diseases

Figure 1 Principles for the diagnosis and management of osteoarthritis

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Phenotypes of osteoarthritis

Box plot of HAQ-DI scores at baseline, week 96 and week 144 categorised by baseline PsA duration. Box plot of HAQ-DI scores at baseline, week 96 and week.

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.

Different treatment strategies in rheumatoid arthritis in relation to radiographic progression (A) number of swollen joints (B) and fatigue severity over.

Nat. Rev. Rheumatol. doi: /nrrheum

Treatment strategy. Treatment strategy. For every patient, changes of treatment were analysed per change, for up to five subsequent therapeutic changes.

Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.

Patient-reported adherence towards different IMID treatments in RA (A), PsA (B) or AS (C). Patient-reported adherence towards different IMID treatments.

Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

Adjusted estimates of DAS28 (95% CI) and RAPID3 (95% CI) scores over time based on multivariate models a priori adjusted for possible confounders: age,

Efficacy in patients who received biologic and nonbiologic disease-modifying antirheumatic drugs in combination with rituximab. aLast-observation carried-forward.

Percentage of patients achieving 20% improvement in the American College of Rheumatology criteria at week 12 by patient demographic and disease characteristics.

Ultrasonographic characteristics and synovitis pattern of patients with inflammatory bowel disease (IBD) with onset of peripheral arthritis under tumour.

Efficacy as first, second and third bDMARD in patients with axial spondyloarthritis. ASAS, Assessment of Spondylo Arthritis international Society; BASDAI,

Design for the long-term extension study RA-BEYOND from randomisation in the originating studies. Design for the long-term extension study RA-BEYOND from.

Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.

Changes over time in DAS 28 (A), SLEDAI (B), glucocorticoid dose (C) and EULAR response (D) in patients with rhupus treated by anti-TNF-α. Box plot (median,

Patient disposition. *Patients who switched multiple times were not included in this analysis; **for patients switching treatment regimens, discontinuations.

Status of tapering in the first year of follow-up.

Post hoc analysis of differences from placebo in the percentage of patients reporting improvements ≥MCID at week 24. Post hoc analysis of differences from.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Suggested therapeutic management according to subtypes and severity of rheumatic immune-related adverse events (irAE). *Add-on therapy with DMARDs (disease-modifying.

Average annual price for csDMARDs (A) and bDMARDs (B) per country in international dollars (light blue) and in euros (dark blue), prices first quarter.

Associations between ‘GDP per capita’ and ‘days to work at the minimum wage to cover 30 days of treatment with a bDMARD’ with ‘% bDMARD use’. bDMARD, biological.

Women With Psoriasis Are Struggling More Than Men

Presentation transcript:

Figure 1 Simplified EULAR and GRAPPA treatment algorithms for predominant peripheral psoriatic arthritis5,6 Figure 1 | Simplified EULAR and GRAPPA treatment algorithms for predominant peripheral psoriatic arthritis5,6. The order of drug use proposed for patients with psoriatic arthritis (PsA) and predominant peripheral joint involvement, with a step-up approach (indicated by staggered boxes) in case of inefficacy or toxicity. *Conditional recommendation in the GRAPPA) guidelines for drugs without current regulatory approval or where recommendations are based on abstract data only. bDMARD, biologic DMARD; csDMARD, conventional synthetic DMARD; EULAR, European League Against Rheumatism; GRAPPA, Group for Research and Assessment of Psoriasisand Psoriatic Arthritis; PDE4, phosphodiesterase 4. Gossec, L. et al. (2016) Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2016.183